XENE: Rasio kapitalisasi pasar marang pendapatan Xenon Pharmaceuticals Inc.
Innovations in ion channels and the success of the drug Azetukalner are driving the growth of Xenon Pharmaceuticals (XENE). The company's normalized P/S ratio reflects the business valuation relative to revenue, while 710.90 captures a new level. High dependence on a single key product creates biotechnological risks. Ultimately, the company is developing an advanced treatment system for severe neurological pathologies.
Rincian analitis perusahaan Xenon Corp (XENE)
- rega saham lan prakiraan rega para ahli:
- informasi kapitalisasi pasar:
- indikator kapitalisasi buku:
- statistik kawajiban utang lan likuiditas:
Rasio Total Utang marang Ekuitas Xenon Pharmaceuticals|XENE - Utang jangka dawa marang modal|Utang jangka cendhak marang modal Xenon Pharmaceuticals|XENE - Gunggung utang perusahaan|Utang marang nilai buku Xenon Corp|XENE - Utang jangka dawa perusahaan|Utang jangka cendhak Xenon Pharmaceuticals|Rasio cepet xenon-pharma.com
- indikator profitabilitas perusahaan lan kelipatan valuasi:
XENE - Penghasilan resik|Bathi resik mangsa ngarep Xenon Pharmaceuticals|XENE - Pangali P/E|Kapitalisasi marang proyeksi bathi Xenon Pharmaceuticals Inc|XENE - Pangali PEG|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Xenon Corp|XENE - Bathi operasional EBITDA|Bathi resik saben saham (EPS TTM) Xenon Pharmaceuticals|XENE - Bathi saben saham sajrone rolas wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan xenon-pharma.com|XENE - Wutah bathi saben saham ing taun lumaku|Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep Xenon Pharmaceuticals
- data total pendapatan lan volume dodolan:
Analisis umum perusahaan:XENE (Xenon)
The P/S ratio evaluates the market value of Xenon Pharmaceuticals (XENE) relative to its annual revenue, allowing investors to determine the premium paid per unit of sales. By analyzing the history of P/S values, where the current level is 710.90, one can correlate capitalization with the efficiency of substance logistics for neuro-research, the continuity and strict adherence to delivery protocols of which form the fundamental basis of the company's cash flow.
Perusahaan pesaing
BIIB (Biogen) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S NBIX (Neurocrine Corp)|Regencell Bioscience - Rasio rega marang pendapatan|Axsome Therapeutics - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan ACAD (ACADIA Pharmaceuticals)|VKTX: Multiplikator P/S|Rasio rega marang dodolan SUPN (Supernus)|CPRX (Catalyst Pharmaceuticals Inc) - Multiplikator P/S|DNLI: Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan harmonybiosciences.com (HRMY)|Biohaven - Rasio kapitalisasi marang pendapatan|Multiplikator P/S AMLX (amylyx.com)|Trevi Pharma (TRVI) - Rega marang dodolan|Praxis Corp - Multiplikator P/S|Anavex Corp (AVXL) - Kapitalisasi marang pendapatan|CBLL: Multiplikator P/S|Prothena Biosciences - Rasio kapitalisasi pasar marang pendapatan|ALEC (alector.com) - Multiplikator P/S|Rasio kapitalisasi marang pendapatan ANNX (Annexon Biosciences)|Rasio rega marang pendapatan Omeros Corporation (OMER)|Neurogene Corp - Rasio kapitalisasi marang pendapatan|Rasio rega marang pendapatan AC Immune S.A. ACIU|Koefisien rega marang pendapatan Voyager Therapeutics (VYGR)|Neumora - Multiplikator P/S|Rasio rega marang dodolan SCLX|Tevogen Bio Inc. (TVGN) - Rasio rega marang pendapatan|Rasio kapitalisasi marang pendapatan ACOG|CGTX (cogrx.com) - Multiplikator P/S|Kapitalisasi marang pendapatan inhibikase.com (IKT)|Rasio rega marang pendapatan Cassava Sciences Inc (SAVA)|Koefisien rega marang pendapatan Assertio|Multiplikator P/S COYA (Coya Therapeutics, Inc.)|Kapitalisasi marang volume dodolan VTGN (VistaGen Therapeutics Inc)|OVID: Kapitalisasi marang pendapatan|ABOS: Rasio rega marang pendapatan|CervoMed (CRVO) - Rasio rega marang pendapatan|Rega marang dodolan Alterity Therapeutics Ltd (ATHE)|CLNN (Clene) - Multiplikator P/S|Rasio kapitalisasi marang pendapatan PEPG (PepGen)|Kapitalisasi marang pendapatan JUNS (Jupiter Neurosciences, Inc.)|Multiplikator P/S relmada.com (RLMD)|Rasio rega marang pendapatan Annovis Bio Corp ANVS|GRCE: Rasio kapitalisasi marang pendapatan|AIFF - Rasio rega marang pendapatan|KLTO (anewmeds.com) - Rasio kapitalisasi marang pendapatan|NRSN (NeuroSense Therapeutics Ltd.) - Kapitalisasi marang pendapatan|revivapharma.com - Rasio kapitalisasi pasar marang pendapatan|MTVA (metaviatx.com) - Multiplikator P/S|NRXS: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S HSDT|PASG - Rega marang dodolan|Multiplikator P/S NEUP (Neuphoria Therapeutics)|NERV: Rasio kapitalisasi marang pendapatan|ATHA: Kapitalisasi marang pendapatan|Addex Therapeutics Ltd - Kapitalisasi marang volume dodolan|Alzamend Neuro, Inc. (ALZN) - Rasio rega marang pendapatan|CYCN (Cyclerion Therapeutics Inc.) - Rasio rega marang pendapatan|Kapitalisasi marang pendapatan PTIX|KTTA: Rasio kapitalisasi pasar marang pendapatan|Kapitalisasi marang pendapatan CRGT (Cortigent Medical)|ATXI (Avenue Therapeutics, Inc.) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Brainstorm Cell Therapeutics, Inc. BCLI|Rasio kapitalisasi pasar marang pendapatan CARA|chromocell.com - Multiplikator P/S|Rasio rega marang dodolan ELYM|ITCI: Multiplikator P/S|Rega marang dodolan Longboard Pharmaceuticals, Inc. (LBPH)|Rasio rega marang pendapatan Marinus Pharmaceuticals, Inc.|NKGN: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S NRBO|SAGE: Rasio rega marang dodolan|Synaptogenix Inc. - Kapitalisasi marang pendapatan|Kapitalisasi marang volume dodolan TRVN (Trevena Inc.)|Vigil Neuroscience, Inc. - Multiplikator P/S|Anew Medical (WENA) - Kapitalisasi marang pendapatan|CERE (Cerevel Corp) - Kapitalisasi marang pendapatan
